We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-12.58%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$43.6B
AUM Growth
-$9.03B
(-17%)
Cap. Flow
-$1.48B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
21.41%
Holding
1,190
New
110
Increased
278
Reduced
409
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$364M |
| 2 |
SIVB
SVB Financial Group
SIVB
|
+$155M |
| 3 |
Textron
TXT
|
+$103M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$102M |
| 5 |
Sanofi
SNY
|
+$96.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$333M |
| 2 |
ExxonMobil
XOM
|
+$242M |
| 3 |
Dollar Tree
DLTR
|
+$231M |
| 4 |
Nutrien
NTR
|
+$213M |
| 5 |
National Vision
EYE
|
+$198M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.53% |
| 2 | Healthcare | 17.73% |
| 3 | Financials | 14.85% |
| 4 | Consumer Discretionary | 9.35% |
| 5 | Industrials | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BTRS
626
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $12M | 0.03% |
2,401,100
+401,100
| +20% | +$2.31M |
|
|
POW
627
DELISTED
Powered Brands Class A Ordinary Shares
POW
| $11.8M | 0.03% |
1,200,000
| – | – |
|
|
FRC
628
DELISTED
First Republic Bank
FRC
| $11.8M | 0.03% |
81,900
-88,900
| -52% | -$13.3M |
|
629
Best Buy
BBY
$18.2B
| $11.8M | 0.03% |
+181,075
| New | +$15.1M |
|
|
ABMD
630
DELISTED
Abiomed Inc
ABMD
| $11.7M | 0.03% |
47,443
-100,100
| -68% | -$27M |
|
|
LDHA
631
DELISTED
LDH Growth Corp I Class A Ordinary Shares
LDHA
| $11.7M | 0.03% |
1,200,000
| – | – |
|
632
Compass Therapeutics
CMPX
$357M
| $11.7M | 0.03% |
4,406,600
+2,129,600
| +94% | +$4.62M |
|
633
BioCryst Pharmaceuticals
BCRX
$2.29B
| $11.7M | 0.03% |
+1,101,611
| New | +$11.4M |
|
634
PTC
PTC
$15.4B
| $11.7M | 0.03% |
109,600
-300
| -0.3% | -$32.4K |
|
635
Halliburton
HAL
$27B
| $11.5M | 0.03% |
368,210
+326,000
| +772% | +$12.2M |
|
|
PXD
636
DELISTED
Pioneer Natural Resource Co.
PXD
| $11.5M | 0.03% |
51,665
-508,015
| -91% | -$129M |
|
637
Nordson
NDSN
$17.3B
| $11.4M | 0.03% |
56,100
-400
| -0.7% | -$85.3K |
|
638
Charles River Laboratories
CRL
$11.3B
| $11.3M | 0.03% |
52,900
+40,200
| +317% | +$9.82M |
|
|
IPG
639
DELISTED
Interpublic Group of Companies
IPG
| $11.3M | 0.03% |
409,989
-1,000
| -0.2% | -$31.7K |
|
640
Verisk Analytics
VRSK
$25.1B
| $11.1M | 0.03% |
64,400
-103,900
| -62% | -$19.4M |
|
|
EGRX
641
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $11.1M | 0.03% |
+250,000
| New | +$11.5M |
|
642
Restaurant Brands International
QSR
$25.6B
| $11.1M | 0.03% |
221,000
+113,000
| +105% | +$6.04M |
|
643
Cogent Biosciences
COGT
$7.32B
| $11.1M | 0.03% |
+1,226,650
| New | +$8.37M |
|
644
American Water Works
AWK
$26.6B
| $11.1M | 0.03% |
+74,333
| New | +$11.3M |
|
645
Vontier
VNT
$4.76B
| $11M | 0.03% |
480,000
+430,000
| +860% | +$11M |
|
646
Third Coast Bancshares
TCBX
$734M
| $11M | 0.03% |
501,290
-54,534
| -10% | -$1.27M |
|
|
AEVA
647
Aeva Technologies
AEVA
$1.4B
| $11M | 0.03% |
700,167
-100,000
| -12% | -$1.65M |
|
648
Lattice Semiconductor
LSCC
$19.6B
| $10.9M | 0.03% |
+225,000
| New | +$11.2M |
|
|
KALV
649
DELISTED
KalVista Pharmaceuticals
KALV
| $10.9M | 0.02% |
1,104,339
+200,000
| +22% | +$2.21M |
|
650
PepGen
PEPG
$133M
| $10.8M | 0.02% |
+1,090,859
| New | +$12.2M |
|
Similar funds
Adage Capital Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Adage Capital Partners held 1,190 positions worth $43.6B, down 17% from $52.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.48B in Q2 2022, closing 115 positions and reducing 409 holdings. Its most notable exit was Nutrien, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Booz Allen Hamilton worth $75.6M.
- Adage Capital Partners's largest Q2 2022 buy was Booz Allen Hamilton: 837,064 shares worth $75.6M.
- Adage Capital Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, an estimated $364M increase.
- Adage Capital Partners's biggest Q2 2022 reduction was Royalty Pharma, cutting an estimated $333M.
- Adage Capital Partners fully exited Nutrien in Q2 2022, selling an estimated $213M.
- Adage Capital Partners's ten largest holdings make up 21% of its $43.6B portfolio in Q2 2022.
- Adage Capital Partners opened 110 new positions and closed 115 in Q2 2022.
- Adage Capital Partners's portfolio value fell 17% quarter-over-quarter to $43.6B.
Based on Adage Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.